Evidence map›Paper›PMID 37384622›Full record

ArticlePLoS pathogens2023

Antigen pressure from two founder viruses induces multiple insertions at a single antibody position to generate broadly neutralizing HIV antibodies.

Collin Joyce, Sasha Murrell, Ben Murrell, Oluwarotimi Omorodion, Lorena S Ver, Nancy Carrico, Raiza Bastidas, Rebecca Nedellec, Michael Bick, Jordan Woehl and 20 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 5 institutions in 3 countries.

Collin JoyceDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.ORCID 0000-0002-8739-3219
Sasha MurrellDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, United States of America.
Ben MurrellDepartment of Medicine, University of California San Diego, San Diego, California, United States of America.
Oluwarotimi OmorodionConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Lorena S VerIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Nancy CarricoIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Raiza BastidasDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Rebecca NedellecDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Michael BickDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Jordan WoehlIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Fangzhu ZhaoDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Alison BurnsIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Shawn BarmanIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Michael AppelIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Alejandra RamosIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Lalinda WickramasingheIAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America.
Kemal ErenDepartment of Medicine, University of California San Diego, San Diego, California, United States of America.
Thomas VollbrechtDepartment of Medicine, University of California San Diego, San Diego, California, United States of America.
Davey M SmithDepartment of Medicine, University of California San Diego, San Diego, California, United States of America.
Sergei L Kosakovsky PondInstitute for Genomics and Evolutionary Medicine, Temple University, Philadelphia, Pennsylvania, United States of America.
Ryan McBrideDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, California, United States of America.
Charli WorthDepartment of Molecular Medicine, The Scripps Research Institute, La Jolla, California, United States of America.
Facundo BatistaConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Devin SokConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
IAVI Protocol C Investigators & The IAVI African HIV Research Network
Pascal PoignardInstitut de Biologie Structurale, Université Grenoble Alpes, Commissariat à l'Energie Atomique, Centre National de Recherche Scientifique and Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.
Bryan BrineyDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.
Ian A WilsonConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.
Elise LandaisConsortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, United States of America.ORCID 0000-0002-8183-5565
Dennis R BurtonDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.ORCID 0000-0001-6711-9864
Scripps Research Institute · USUniversity of California San Diego · USCentre Hospitalier Universitaire de Grenoble · FRKarolinska Institutet · SETemple University · US

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Structural Basis of Immune Recognition of Glycosylated AntigensU54GM062116 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI ALVAREZ, RICHARD · 2001 to 2010
$80.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SONIA JAIN · 1994 to 2026
$78.4M
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Ritimukta Sarangi · 2020 to 2026
$43.3M
User Training & OutreachP30GM138396 · NIGMS · UCHICAGO ARGONNE, LLC · PI JANET L. SMITH · 2020 to 2026
$34.3M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2018 to 2026
$32.0M
Viral correlates of neutralizing antibody responseU19AI090970 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI POIGNARD, PASCAL · 2010 to 2014
$9.3M
The Multi-omics Vaccine Evaluation (MOVE) ConsortiumP01AI177683 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Bryan Briney · 2023 to 2026
$9.0M
High-Speed High-Sensitivity Detector for X-ray Micro-Crystallography at GM/CA@APSS10OD012289 · OD · UNIVERSITY OF CHICAGO · PI FISCHETTI, ROBERT F. · 2014 to 2014
$2.0M
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P01 AI177683NIAID NIH HHS P30 AI036214NIAID NIH HHS U19 AI090970NIAID NIH HHS U19 AI135995NIAID NIH HHS UM1 AI144462NIGMS NIH HHS P30 GM133894NIGMS NIH HHS P30 GM138396NIGMS NIH HHS U54 GM062116NIH HHS S10 OD012289
6 · The paper itself

Abstract

Vaccination strategies aimed at maturing broadly neutralizing antibodies (bnAbs) from naïve precursors are hindered by unusual features that characterize these Abs, including insertions and deletions (indels). Longitudinal studies of natural HIV infection cases shed light on the complex processes underlying bnAb development and have suggested a role for superinfection as a potential enhancer of neutralization breadth. Here we describe the development of a potent bnAb lineage that was elicited by two founder viruses to inform vaccine design. The V3-glycan targeting bnAb lineage (PC39-1) was isolated from subtype C-infected IAVI Protocol C elite neutralizer, donor PC39, and is defined by the presence of multiple independent insertions in CDRH1 that range from 1-11 amino acids in length. Memory B cell members of this lineage are predominantly atypical in phenotype yet also span the class-switched and antibody-secreting cell compartments. Development of neutralization breadth occurred concomitantly with extensive recombination between founder viruses before each virus separated into two distinct population "arms" that evolved independently to escape the PC39-1 lineage. Ab crystal structures show an extended CDRH1 that can help stabilize the CDRH3. Overall, these findings suggest that early exposure of the humoral system to multiple related Env molecules could promote the induction of bnAbs by focusing Ab responses to conserved epitopes.

Indexed as

DermatitisHIV-1HIV InfectionsBroadly Neutralizing AntibodiesEpitopesHIV AntibodiesHumansBroadly Neutralizing AntibodiesEpitopesHIV Antibodies

Identifiers

PMID37384622
PMCPMC10309625
OpenAlexW4382631030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.